Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
Abstract The combination of cyclin dependent kinase 4/6 inhibitors with endocrine therapy is the standard therapy in hormone receptor positive HER-2 negative metastatic breast cancer (HR+/HER2− MBC). Several randomized trials have shown the benefits of this combination, however, real world evidence...
Guardado en:
Autores principales: | Chaturbhuj Agrawal, Pankaj Goyal, Amit Agarwal, Rupal Tripathi, Chandragouda Dodagoudar, Saphalta Baghmar, Archana Sharma, Ullas Batra, Vineet Talwar, Sumit Goyal, Rajeev Kumar, Dinesh Chandra Doval |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0a2eee6afaf34fa489c4e65d644828a3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab M, et al.
Publicado: (2016) -
Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice.
por: Sushmita Rath, et al.
Publicado: (2021) -
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
por: Cadoo KA, et al.
Publicado: (2014) -
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
por: R.K. Ismail, et al.
Publicado: (2021) -
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
por: Ben O’Leary, et al.
Publicado: (2018)